
-
Verve Therapeutics NASDAQ:VERV Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.
Location: | Website: www.vervetx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
147.7M
Cash
539.9M
Avg Qtr Burn
-39.38M
Short % of Float
21.76%
Insider Ownership
5.29%
Institutional Own.
94.50%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VERVE-102 (PCSK9) Details Hypercholesterolemia | Phase 1b Data readout | |
VERVE-101 (PCSK9) Details Hypercholesterolemia | Phase 1b Update | |
VERVE-201 (ANGPTL3) Details Hypercholesterolemia | Phase 1b Update |